Skip to main content
TipRanks
Go Ultimate75% OFF

Sernova (PSH0) AI Stock Analysis

3 Followers
DE:PSH0

Sernova

(XETRA:PSH0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Scalable Cell-Therapy PlatformSernova’s implantable Cell Pouch System is designed to support therapeutic cells inside the body, creating a platform that may address more than one chronic disease application. If clinical development succeeds, this common architecture could support broader commercialization than a single-program therapy.
Negative Factors
No Commercial RevenueSernova has not yet established a commercial revenue base, so its economic model remains dependent on clinical progress, regulatory approval, and future financing or partnerships. Without product sales, there is no demonstrated market traction or internally generated funding stream to support ongoing development.

Sernova (PSH0) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%150%DE:PSH0-29.76%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 33.99M
Dividend Yield
―
Average Volume (3M)
36.46K
Price to Earnings (P/E)
-3.1
Beta (1Y)
0.37
Revenue Growth
―
EPS Growth
50.81%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sernova Business Overview & Revenue Model

Company Description

Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technolo...

Sernova Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PSH0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:COVTSE:COV79OutperformCAD 102.74M23.6515.04%―4.11%88.39%
TSE:MBXTSE:MBX52NeutralCAD 40.41M-8.36-18.83%―-27.13%-1752.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:MIRTSE:MIR47NeutralCAD 38.60M-12.5012.68%―45.72%35.82%
TSE:DTCTSE:DTC38UnderperformCAD 19.41M-2.31-424.91%――-54.70%
TSE:NRXTSE:NRX33UnderperformCAD 38.10M-4.49-337.24%――19.02%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:PSH0TSE:COVTSE:MBXTSE:MIRTSE:NRXTSE:DTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PSH0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PSH0Sernova Corp0.06-0.03-29.76%
TSE:COVCovalon Technologies3.721.7891.75%
TSE:MBXMicrobix Biosystms0.290.0418.00%
TSE:MIRMedmira Inc0.06-0.02-21.43%
TSE:NRXNurexone Biologic Inc.0.49-0.26-34.67%
TSE:DTCDefence Therapeutics Inc0.26-0.53-67.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.